Impact of Clinical Trials in Rare Disease and Oncology

Previous Article
We need faster endpoints for targeted cancer drugs, and there is one
We need faster endpoints for targeted cancer drugs, and there is one

As a former regulator, Jorge shares his perspectives for the need of more faster endpoints to measure how t...

Next Video
Leveraging Real-world Evidence in a Rare Disease Oncology Drug Approval
Leveraging Real-world Evidence in a Rare Disease Oncology Drug Approval

Parexel experts discuss a recent project involving a Rare Disease Oncology therapeutic, in which our expert...

×

Let's start a conversation...

First Name
Last Name
Job Title
Company Name
Country
Therapeutic Area Interest - optional
Tell us how we can help
Thank you! We'll be in touch soon.
Error - something went wrong!